select a format

Single User License
USD 2000 INR 130880
Site License
USD 4000 INR 261760
Corporate User License
USD 6000 INR 392640

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Heart Transplant Rejection-Pipeline Review, H2 2016

Heart Transplant Rejection-Pipeline Review, H2 2016


  • Products Id :- GMDHC8886IDB
  • |
  • Pages: 31
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Heart Transplant Rejection-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heart Transplant Rejection-Pipeline Review, H2 2016, provides an overview of the Heart Transplant Rejection (Immunology) pipeline landscape.

Heart transplantation is the therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heart Transplant Rejection-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Heart Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heart Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Heart Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 5 respectively.

Heart Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Heart Transplant Rejection (Immunology).

The pipeline guide reviews pipeline therapeutics for Heart Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Heart Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Heart Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Heart Transplant Rejection (Immunology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Heart Transplant Rejection (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Heart Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Heart Transplant Rejection Overview 5

Therapeutics Development 6

Pipeline Products for Heart Transplant Rejection-Overview 6

Pipeline Products for Heart Transplant Rejection-Comparative Analysis 7

Heart Transplant Rejection-Therapeutics under Development by Companies 8

Heart Transplant Rejection-Pipeline Products Glance 9

Early Stage Products 9

Heart Transplant Rejection-Products under Development by Companies 10

Heart Transplant Rejection-Companies Involved in Therapeutics Development 11

Astellas Pharma Inc 11

Nekonal Sarl 12

Noxxon Pharma AG 13

Pelican Therapeutics Inc 14

Heart Transplant Rejection-Therapeutics Assessment 15

Assessment by Monotherapy Products 15

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Drug Profiles 23

AS-2521780-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

emapticap pegol-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

PTX-15-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Small Molecule to Inhibit JAK3 for Heart Transplantation-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Heart Transplant Rejection-Dormant Projects 29

Appendix 30

Methodology 30

Coverage 30

Secondary Research 30

Primary Research 30

Expert Panel Validation 30

Contact Us 30

Disclaimer 31

List of Figures

Number of Products by Top 10 Targets, H2 2016 16

Number of Products by Stage and Top 10 Targets, H2 2016 16

Number of Products by Top 10 Mechanism of Actions, H2 2016 18

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

List of Tables

Number of Products under Development for Heart Transplant Rejection, H2 2016 6

Number of Products under Development for Heart Transplant Rejection-Comparative Analysis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Early Stage Development, H2 2016 9

Products under Development by Companies, H2 2016 10

Heart Transplant Rejection-Pipeline by Astellas Pharma Inc, H2 2016 11

Heart Transplant Rejection-Pipeline by Nekonal Sarl, H2 2016 12

Heart Transplant Rejection-Pipeline by Noxxon Pharma AG, H2 2016 13

Heart Transplant Rejection-Pipeline by Pelican Therapeutics Inc, H2 2016 14

Assessment by Monotherapy Products, H2 2016 15

Number of Products by Stage and Target, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 22

Heart Transplant Rejection-Dormant Projects, H2 2016 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Astellas Pharma Inc, Nekonal Sarl, Noxxon Pharma AG, Pelican Therapeutics Inc

Heart Transplant Rejection Therapeutic Products under Development, Key Players in Heart Transplant Rejection Therapeutics, Heart Transplant Rejection Pipeline Overview, Heart Transplant Rejection Pipeline, Heart Transplant Rejection Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com